J0691 HCPCS Level II code: Injection, lefamulin, 1 mg
J0691 is the HCPCS code for “Injection, lefamulin, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0691Injection, lefamulin, 1 mg
Short description: Inj lefamulin 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J0691 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jul 1, 2020
Where J0691 sits
- 1J codesDrugs administered other than orally
- 2Active code J0691Injection, lefamulin, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0691 mean?
J0691 is the HCPCS code for “Injection, lefamulin, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0691?
CMS lists J0691’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0691
All J codesJ0675Injection, carboprost tromethamine, 0.1 mgJ0681Injection, ceftobiprole medocaril sodium, 3 mgJ0687Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mgJ0688Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mgJ0689Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mgJ0690Injection, cefazolin sodium, 500 mgJ0692Injection, cefepime hydrochloride, 500 mgJ0693Injection, cefiderocol, 5 mgJ0694Injection, cefoxitin sodium, 1 gmJ0695Injection, ceftolozane 50 mg and tazobactam 25 mgJ0696Injection, ceftriaxone sodium, per 250 mgJ0697Injection, sterile cefuroxime sodium, per 750 mg